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Aim To assess the association between ABO blood group 
genotypes and genetic risk factors for thrombosis (FV 
Leiden, prothrombin G20210A, and methylenetetrahydro-
folate reductase C677T mutations) in the Croatian popula-
tion and to determine whether genetic predisposition to 
thrombotic risk is higher in non-OO blood group geno-
types than in OO blood group genotypes.
Methods The study included 154 patients with thrombo-
sis and 200 asymptomatic blood donors as a control group. 
Genotyping to 5 common alleles of ABO blood groups was 
performed by polymerase chain reaction with sequence 
specific primers (PCR-SSP). FV Leiden was determined by 
PCR-SSP, while prothrombin and methylenetetrahydro-
folate reductase were determined by PCR and restriction 
fragment length polymorphism (PCR-RFLP).
Results There was an association between non-OO blood 
group genotypes and the risk of thrombosis (odds ra-
tio [OR] 2.08, 95% confidence interval [CI], 1.32-3.27). The 
strongest association with thrombotic risk was recorded 
for A1B/A2B blood group genotypes (OR, 2.73; 95% CI, 1.10-
6.74), followed by BB/O1B/O2B (OR, 2.29; 95% CI, 1.25-4.21) 
and O1A1/O2A1 (OR, 1.95; 95% CI, 1.15-3.31). FV Leiden in-
creased the risk of thrombosis 31-fold in the group of OO 
carriers and fourfold in the group of non-OO carriers. There 
was no significant difference in the risk of thrombosis be-
tween OO and non-OO blood groups associated with pro-
thrombin mutation. Non-OO carriers positive for methy-
lenetetrahydrofolate reductase had a 5.7 times greater risk 
of thrombosis than that recorded in OO carriers negative 
for methylenetetrahydrofolate reductase.
Conclusion Study results confirmed the association of 
non-OO blood group genotypes with an increased risk of 
thrombosis in Croatia.
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ABO gene is located on chromosome 9 and its inheritance 
is explained by the Mendel and Bernstein three-allele the-
ory. Methods of serologic typing allow the determination 
of 6 main phenotypes: A, B, A2, A2B, AB, and O. Methods of 
molecular biology allow the differentiation of 5 common 
alleles: O1, O2, A1, A2, and B; and 15 genotypes. ABO system 
is very well characterized by more than 165 alleles. Popu-
lation studies have documented different frequencies of 
particular ABO genotypes worldwide (1). Also, there have 
been reports on a lower or higher association between 
ABO blood groups and cardiovascular, gastrointestinal, 
and infectious diseases (2).
The association of ABO blood groups and diseases result-
ing in coagulation impairment and venous thrombus for-
mation was first described by Jick et al (3). Most studies 
performed to date have generally agreed that non-OO 
blood group carriers have a higher risk of thrombosis than 
OO blood group carriers (4-7). Wu et al (8) believe that the 
introduction of ABO typing in the evaluation of thrombo-
philia patients should be considered in A1A1/A1B and BB 
genotypes with elevated von Willebrand factor (vWF) anti-
gen levels in particular.
Bezemer and Rosendaal (9) investigated new predictive 
genetic variants for venous thrombosis and identified ABO 
blood groups, fibrinogen gene haplotypes, factor V, factor 
VIII, and factor XIII Val34Leu polymorphisms as the possible 
new predictive variants for the disease development.
Blood group O shows a tendency to bleeding and blood 
group A to clotting, due to the higher level of coagulation 
factors VIII and vWF in these individuals. The ABO blood 
groups also determine plasma levels of vWF, which is by 25-
30% lower in O blood group than in non-O blood group. 
This occurs due to the direct functional impact of ABO locus; 
however, the exact mechanism has not yet been elucidated. 
Theoretically, ABO blood group can modify the rate of vWF 
synthesis or its secretion within endothelial cells, or act upon 
vWF catabolism, ie, proteolysis and/or plasma clearance (10).
Venous thrombosis and disorders associated with coro-
nary artery disease are vascular diseases in which both in-
herited and acquired factors are involved. It is of utmost 
importance to identify the risk factors implicated in the dis-
ease development and the candidates eligible for antico-
agulant therapy to prevent recurrent thrombotic episodes. 
The most common inherited prothrombotic risk factors 
with significant impact on the development of thrombosis 
are mutations of the genes encoding proteins involved in 
the coagulation cascade, such as FV Leiden mutation and 
G20210A mutation of the prothrombin gene (11). In ad-
dition to coagulation factors, mutation of the methylene-
tetrahydrofolate reductase gene, known to influence the 
development of atherosclerosis and vascular diseases, has 
also been extensively investigated (12). It should be noted 
that the thrombogenic impact of homozygosity for meth-
ylenetetrahydrofolate reductase C677T mutation is only 
pronounced in case of its association with mild or mod-
erate hyperhomocysteinemia and the genetic mutations 
mentioned above (13,14).
The aim of this study was to define ABO genotypes in the 
population of Croatian blood donors and to assess the im-
pact of ABO blood group genotypes and FV Leiden, pro-
thrombin G20210A, and methylenetetrahydrofolate reduc-
tase C677T mutations on thrombosis development in the 
Croatian population. In addition, we investigated whether 
predisposition to thrombosis was higher in non-OO geno-
type carriers than in OO genotype carriers. Genotyping at 
5 common alleles (O1, O2, A1, A2, and B) was used for ABO 
blood group determination because it provides more in-
formation on homozygous and heterozygous carriers of 
A, B, and O alleles than serotyping. The risk of thrombosis 
caused by a combination of multiple genetic factors (inter-
action of 2 risk factors) was also assessed.
ParTICIPanTs anD MeThoDs
Participants
A total of 154 out-patients treated at Coagulation Depart-
ment, Croatian Institute of Transfusion Medicine, Zagreb, 
Croatia, from 2005 until 2007 were included in the study. 
They were referred to our institution for an evaluation of 
hemostatic parameters with disease follow-up. There were 
100 female and 54 male patients with median age of 46 
years (18-86 years); 74 and 80 patients were aged ≤45 and 
>45, respectively. According to the diagnosis made on the 
initial thrombotic episode by ultrasonography, venogra-
phy/phlebography, coagulation tests, and history data, pa-
tients were divided into 3 subgroups: venous thromboem-
bolism (VTE) (n=60, 36 female/24 male, median age 46 
years, range 18-86); chronic venous diseases (CVD) (n=69, 
48 female/21 male, median age 50 years, range 19-81); and 
arterial thrombosis (n=25, 16 female/9 male, median age 
39 years, range 20-64). The VTE subgroup included pa-
tients with deep vein thrombosis and pulmonary embo-
lism. The CVD subgroup included patients with throm-
bophlebitis and varicosity. The arterial thrombosis 
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subgroup included patients with thrombosis of the intra-
arterial vascular system such as stroke, myocardial infarc-
tion, and atrial fibrillation, and those with coagulation and 
circulation disorders.
Control group comprised 200 asymptomatic and healthy 
blood donors (87 female/113 male) without history of 
thrombosis and free from vascular diseases during the 
2005-2006 period. Median age of control participants was 
40 years. All participants in the control group were from 
the same geographic region; there were 119 and 81 par-
ticipants aged ≤45 and >45, respectively.
Data on age, sex, and genetic factors for thrombosis in the pa-
tient and control group are summarized in Table 1. Whereas 
patient group showed a female predominance (100 female 
vs 54 male), in control group the sex ratio was more balanced 
(87 female vs 113 male). The groups with VTE, CVD, and ar-
terial thrombosis did not differ significantly with respect to 
age (median test; overall median, 46.0, χ2=3.375, P=0.185; 
Kruskal Wallis analysis of variance, H=2.862, P=0.239).
However, patient groups were significantly older than the 
control group (median test; overall median, 43.5, χ2=10.328, 
P=0.016; Kruskal Wallis analysis of variance, H=16.068, 
P=0.001), particularly VTE and CVD groups that were signif-
icantly older than control group (median test, VTE vs con-
trol, P=0.005, CVD vs control P=0.016).
In control group, the distribution of ABO blood group phe-
notypes was as follows: group O – 86 (43%); group A – 72 
(36%); group B – 32 (16%); and group AB – 10 (5%) partici-
pants. The procedures used in the study were in accor-
dance with ethical standards of the responsible com-
mittee on human experimentation (institutional or 
regional) or with the 2008 revision of the Helsinki Decla-
ration. An informed consent was obtained from all study 
participants prior to entering the study.
aBo genotyping by polymerase chain reaction with 
sequence specific primers
Genomic DNA isolation from EDTA blood samples was 
performed by the commercial spin column procedure 
QiaAmp DNA Mini kit (Qiagen, Hilden, Germany). ABO gen-
otypes were determined in 8 parallel PCR-SSP reactions to 
amplify exons 6 and 7 of the ABO blood group gene, ac-
cording to Gassner (15), with some modifications in primer 
dilution and PCR conditions. For each PCR assay, a master 
mix (20.0 μL) was prepared consisting of 2.0 μL of 10×PCR 
buffer +1.5 mM MgCl2 and 0.8 μL of 2 nM dinucleotide tri-
phosphate mix (0.25 μL each). The concentration of spe-
cific primers was 1 μM, concentration of internal control 
(human growth hormone) 0.1 μM, bidistilled H2O, 0.1 μL, 
Taq polymerase (AmpliTaq DNA polymerase, Applied Bio-
systems, Branchburg, NJ, USA) 5 U/μL, and 1.5-2.0 μL of a 
solution of 10 μg/mL DNA.
The PCR protocol was carried out under the following con-
ditions: denaturation of DNA at 96°C for 2 minutes, 5 cycles 
– at 96°C for 25 seconds, 70°C for 50 seconds, and 72°C for 
45 seconds, 25 cycles – at 96°C for 25 seconds, 65°C for 50 
seconds, and 72°C for 45 seconds, and additional 10 cycles 
– at 96°C for 25 seconds, 61°C for 50 seconds, and 72°C for 
45 seconds.
PCR products (20 μL) were run on a standard 2% agarose 
gel. The presence of gene fragment of the human growth 
hormone (internal control) in each SSP reaction showed 
that amplification was successful. The ABO alleles and gen-
TaBle 1. Data on age, sex, and genetic factors for thrombosis in patient and control groups
no. (%) of no. (%) of patients with

















 36 (60)  24 (40)  30 (50) 30 (50) 46 (18-86) 16 (26.7) 1 (1.7) 5 (8.3) 14 (23.3)
Chronic venous disease 
(n=69)
 48 (69.6)  21 (30.4)  29 (42) 40 (58) 50 (19-81) 13 (18.8)   – 1 (1.4) 10 (14.5)
Arterial disease 
(n=25)
 16 (64)   9 (36)  15 (60) 10 (40) 39 (20-64)  3 (12) 1 (4) 2 (8)  2 (8)
Total 100 (64.9)  54 (34.1)  74 (48) 80 (52) 46 (18-86) 32 (20.8) 2 (1.3) 8 (5.2) 26 (16.9)
Control group 
(n=200)
 87 (43.5) 113 (56.5) 119 (59.5) 81 (40.5) 40 (18-76)  7 (3.5)   – 7 (3.5) 21 (10.5)
*abbreviations: FVl – factor V leiden; FII – prothrombin; MThFr – methylenetetrahydrofolate reductase.
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otypes were named according to the nomenclature used 
by Yamamoto (1).
analysis of FV leiden mutation by PCr-ssP method
FV Leiden genotyping was performed by PCR-SSP ampli-
fication of extracted DNA in two separate reactions, one 
containing primers for the wild type allele and the other 
containing primers for the mutant allele (16). PCR prod-
ucts (20 μL) were run on a standard 1.5% agarose gels. PCR 
product for wild type is 149 bp and for mutant allele 174 
bp. Internal control for co-amplification in each SSP reac-
tion was β-actin gene fragment of 310 bp.
analysis of prothrombin G20210a mutation by 
polymerase chain reaction and restriction fragment 
length polymorphism (PCr-rFlP)
The prothrombin G20210A mutation was identified by PCR 
amplification, followed by RFLP digestion (17). PCR product 
of mutated site was digested with Hind III in the 10X buffer 
(Invitrogen, Carlsbad, CA, USA). The digestion mix (20 μL) 
containing 2 U of Hind III and 10 μL of PCR product was 
incubated for 3-4 h at 37°C. Restriction products were sep-
arated on 3% agarose gel. Participants with normal gen-
otype had a wild type fragment of 345 bp, homozygous 
carriers of mutant allele were identified by the presence of 
a 322 bp fragment, and heterozygous carriers had both al-
leles, yielding both fragments on agarose gel (17).
analysis of methylenetetrahydrofolate reductase C677T 
mutation by PCr-rFlP method
The methylenetetrahydrofolate reductase C677T mutation 
was amplified using primers described by Frosst et al (18), 
where the PCR fragment was digested by Hinf I. The PCR 
product of mutated site was digested with Hinf I in 10X 
buffer (Invitrogen, Carlsbad, CA, USA). The digestion mix 
(20 μL) containing 2 U of Hinf I and 10 μL of PCR product 
was incubated for 3-4 h at 37°C. Restriction products were 
separated on 3% agarose gel. Normal genotype was iden-
tified by the presence of a wild type fragment of 198 bp, 
whereas mutant homozygous carriers were identified by 
the presence of a 175-bp fragment and heterozygous car-
riers by the presence of both fragments (18).
statistical analysis
Results were obtained by calculation of odds ratio (OR) of 
the data from contingency tables (incidences), with 95% 
confidence interval (95% CI) calculation based on large 
sample approximation to the sampling distribution of the 
log odds ratio. OR calculation was used to assess the im-
pact of combinations of ABO blood group genotypes and 
genetic risk factors on thrombosis development. Fisher ex-
act test was used in the analysis of contingency tables with 
small sample sizes. The level of statistical significance was 
set at 0.05 in all analyses (MedCalc software version 4.10 for 
Windows 95, MedCalc Software; Mariakerke, Belgium).
resulTs
Prevalence of genetic factors for thrombosis
Thirty-two heterozygous and 2 homozygous carriers of FV 
Leiden were found in the patient group as opposed to only 
7 heterozygous carriers in the control group. Also, 8 and 7 
heterozygous carriers of prothrombin G20210A mutation, 
and 26 and 21 homozygous methylenetetrahydrofolate re-
ductase carriers were recorded in the patient and control 
group, respectively.
Prevalence of aBo genotypes
Three homozygous ABO genotypes, ie, O2O2, A2A2, and BB, 
were not found in the patient and control group, whereas 
other 3 genotypes, O2A2, O2B, and A2B, were very rare and 
were only present in the patient group (Table 2).
oo and non-oo genotype carriers and risk of thrombosis
Non-OO blood group carriers from both patient and 
control group had higher probability of developing 







O O1O1  37 (24.1)  81 (40.5)
O1O2  4 (2.6)   5 (2.5)
A O1A1  51 (33.2)  52 (26)
O1A2   3 (1.9)  5 (2.5)
O2A1   1 (0.6)  4 (2)
A1A1   8 (5.2)  7 (3.5)
A1A2   1 (0.6)  4 (2)
O2 A2   1 (0.6)   –
B O1B  34 (22.2)  32 (16)
O2B   1 (0.6)   –
AB A1B  12(7.8)  10 (5)
A2B   1(0.6)   –
n 154 200
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thrombosis than OO-carriers (OR, 2.08; 95% CI, 1.32-3.27, 
P=0.001).
Genotype comparison between non-OO and OO carriers 
revealed genotypes with A and B alleles to pose a slightly 
elevated thrombotic risk. OR was 1.95 (95% CI, 1.15-3.31) 
for O1A1/O2A1 genotypes; 2.29 (95% CI, 1.25-4.21) for BB/ 
O1B/ O2B genotypes; and was highest for A1B/A2B geno-
types (OR, 2.73; 95% CI, 1.10-6.74). A1A1 genotype (OR, 
2.40; 95% CI, 0.81-7.06), A1A2 genotype (OR, 0.52; 95% CI: 
0.06-4.84), and O1A2/O2A2/A2A2 genotype (OR, 1.68; 95% CI, 
0.43-6.58) were not found to be significant risk factors for 
thrombosis (Table 3).
Combined effect of oo and non-oo blood group 
carriers and genetic factors for thrombosis
Table 4 shows the comparison of OO and non-OO blood 
group carriers of FV Leiden, FII prothrombin (G20210A), 
and methylenetetrahydrofolate reductase (677TT) as ge-
netic factors for thrombosis. In the group of OO carriers, 
the presence of FV Leiden mutation increased the risk of 
thrombosis (OR, 31.2; 95% CI, 3.9-251.7). Comparison of OO 
carriers without FV Leiden mutation and non-OO carriers 
with FV Leiden mutation showed the risk of thrombosis 
to be tenfold in the latter (OR, 9.9; 95% CI, 3.7-26.9). Only 
FV Leiden heterozygous carriers were included in the cal-
culations because there were no homozygous carriers in 
control group to be compared with 2 homozygous carri-
ers in patient group. In contrast to FV Leiden mutation, the 
presence of prothrombin gene G20210A mutation had no 
significant impact on the development of thrombosis in 
either OO or non-OO carriers. Testing the thrombogenic 
effect of homozygosity for methylenetetrahydrofolate re-
ductase C677T mutation indicated the non-OO carriers 
with methylenetetrahydrofolate reductase C677T muta-
tion to be at a twofold risk of thrombosis compared with 
non-OO carriers without methylenetetrahydrofolate reduc-
tase C677T mutation (OR, 1.90; 95% CI, 1.20-3.24). Although 
a few tests resulted with poor statistical power, the aver-
TaBle 3. Comparison of oo and non-oo genotype carriers in risk for development of thrombosis*
Genotype of 
non-oo blood groups








A1A1  8 (53.3)  7 (46.7)  15 2.40 (0.81-7.06) 0.149
A1A2  1 (20)  4 (80)   5 0.52 (0.06-4.84) 1.000
O1A1/O2A1 52 (48.1) 56 (51.9) 108 1.95 (1.15-3.31) 0.016
O1A2/ O2A2/A2A2  4 (44.4)  5 (55.6)   9 1.68 (0.43-6.58) 0.478
BB/ O1B/ O2B 35 (52.2) 32 (47.8)  67 2.29 (1.25-4.21) 0.009
A1B/ A2B 13 (56.5) 10 (43.4)  23 2.73 (1.10-6.74) 0.034
*Blood group genotypes o1o1/o1o2 were used as reference category.
TaBle 4. Comparison of oo and non-oo blood group carriers of FV leiden (FVl), FII prothrombin (G20210a) and methylenetetrahy-
drofolate reductase (677TT) as genetic factors for thrombosis
Blood group genotype and 
genetic factors for thrombosis
no. (%) of patients 
with thrombosis (n=154)








OO and FVL (-)  30 (19.7)  85 (42.5) 1† 0.99
OO and FVL (+)  11 (7.2)   1 (0.5) 31.2 (3.86-251.74) <0.001 0.91
Non-OO and FVL (-)  90 (59.3) 108 (54) 2.40 (1.40-3.85) <0.001 0.65
Non-OO and FVL (+)  21 (13.8)   6 (3) 9.92 (3.65-26.91) <0.001 0.96
OO and FII(-)  38 (24.7)  85 (42.5) 1† 0.96
OO and FII (+)   3 (1.9)   1 (0.5) 6.71 (0.68-66.62)‡   0.099 0.86
Non-OO and FII (-) 108 (70.2) 108 (54) 2.2 (1.40-3.60) <0.001 0.88
Non-OO and FII (+)   5 (3.2)   6 (3) 1.86 (0.54-6.48)‡   0.330 0.76
OO and MTHFR (-)  33 (21.4)  72 (36) 1† 0.85
OO and MTHFR (+)   8 (5.2)  14 (7) 1.25 (0.48 – 3.30)‡   0.627 0.66
Non-OO and MTHFR (-)  95 (61.7) 107 (53.5) 1.90 (1.20-3.20)   0.010 0.53
Non-OO and MTHFR (+)  18 (11.7)   7 (3.5) 5.61 (2.14-14.73) <0.001 0.86
*abbreviations: FVl – factor V leiden; FII – prothrombin; MThFr – methylenetetrahydrofolate reductase.
†reference category.
‡statistically non-significant.
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age power of the analyses performed was larger than 0.80 
(Table 4). Table 5 shows the comparison between OO and 
non-OO blood group carriers of prothrombotic risk factors 
restricted only to venous thrombosis. The OR calculations 
and Fisher test results did not show significant differences 
in comparison with the results presented in Table 4.
DIsCussIon
The results of the present study indicate the non-OO blood 
group carriers to be at a significant, twofold risk of throm-
bosis compared with OO blood group carriers. Genotype 
analysis of non-OO carriers showed the highest risk of 
thrombosis in carriers of AB and A2B genotypes, followed 
by BB/O1B/O2B genotypes and O1A1/O2A1 genotypes.
Accordingly, the significant risk of thrombosis was higher 
in the carriers of B alleles than in those carrying A alleles. 
Based on the study results, A2 allele did not appear to be 
a thrombotic risk factor, as demonstrated in A1A2 (OR 0.52) 
and O1A2/O2A2/A2A2 (OR 1.68) genotypes. Yet, A2 allele was 
present in A2B genotype, which is considered as a throm-
botic risk factor due to the presence of B allele. Unfortu-
nately, the number of patients and controls with some rare 
genotypes was too small to draw definite conclusions on 
these associations. The Netherlands’ large LETS study per-
formed by Morelli et al (19) showed the non-OO genotype 
to be a significant risk factor for venous thrombosis, with 
OR 1.8 (95% CI, 1.4-2.4), which is comparable to our results 
(OR, 2.08). They concluded that all non-OO genotypes ex-
cept A2 homozygotes or O1A2 combinations were associat-
ed with an increased risk of thrombosis, which is consistent 
with our results, with the exception of A1A1 genotype. Simi-
larly, a meta-analysis of studies on the association between 
vascular disease and ABO showed pooled OR for venous 
thromboembolism to be 1.79 (8).
Studies on arterial thrombotic diseases reported similar but 
less pronounced association with non-OO blood groups 
as studies on venous thrombosis or even failed to confirm 
it. In a study on the association of ABO system and acute 
myocardial infarction in Switzerland, Nydegger et al (7) 
found B allele to be an independent risk factor for myocar-
dial infarction (OR, 2.7). In addition, homozygous carriers of 
BB blood group showed the highest level of vWF, which is 
known to increase the risk of myocardial infarction. B anti-
gen additionally contributes to the increased platelet ag-
gregation. Wu et al (8) defined pooled OR of 1.25 for myo-
cardial infarction and 1.14 for cerebral ischemia of arterial 
origin. In a study including Iranian patients with coronary 
artery disease, Amirzadegan et al (4) found no association 
with particular ABO blood groups.
Our results showed the presence of FV Leiden mutation to 
increase the risk of thrombosis by as many as 31 times in 
OO genotypes and about 4 times in non-OO genotypes. 
Too high OR (31.2) in OO genotypes is a consequence of 
having only one person with FV Leiden mutation in the 
control group and a wide confidence interval is a conse-
quence of the small sample size. If two persons had had 
FV Leiden mutation, the OR would have been cut in 
half. This shows the limitation of statistical analysis 
TaBle 5. Comparison of oo and non-oo blood group carriers of prothrombotic risk factors in patients with venous thrombosis
Blood group genotype and 
genetic factors for thrombosis
no. of patients 
with venous thrombosis (n=129)






OO and FVL (-) 26  85 (42.5) 1†
OO and FVL (+) 10   1 (0.5) 32.7 (4.0-267.5) <0.001
Non-OO and FVL (-) 73 108 (54) 2.2 (1.3-3.8)   0.002
Non-OO and FVL (+) 19   6 (3) 10.4 (3.7-28.6) <0.001
OO and FII(-) 33  85 (42.5) 1†
OO and FII (+)  3   1 (0.5) 7.7 (0.8-77.0)‡   0.076
Non-OO and FII (-) 90 108 (54) 2.1 (1.3-3.5)   0.001  
Non-OO and FII (+)  3   6 (3) 1.3 (0.3-5.5)‡   0.712
OO and MTHFR (-) 29  72 (36) 1†
OO and MTHFR (+)  7  14 (7) 1.2 (0.5-3.4)‡   0.793
Non-OO and MTHFR (-) 76 107 (53.5) 1.8 (1.0-3.0)   0.039
Non-OO and MTHFR (+) 17   7 (3.5) 6.0 (2.3-16.1) <0.001
*abbreviations: FVl – factor V leiden; FII – prothrombin; MThFr – methylenetetrahydrofolate reductase.
†reference category.
‡statistically non-significant.
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used on a small number of study participants. In non-OO 
carriers positive for FV Leiden mutation, the risk of throm-
bosis was tenfold compared with that recorded in OO car-
riers negative for FV Leiden mutation. According to Morelli 
et al (19), OO carriers negative for FV Leiden in combina-
tion with OO FV Leiden positive carriers had an increased 
risk of thrombosis, with OR 4.6 (95% CI, 2.0-10.1), where-
as a combination of OO FV Leiden negative carriers with 
non-OO FV Leiden positive carriers yielded OR 23.2 (95% 
CI, 9.1-59.3). Despite different OR values obtained in our 
study and those reported in the studies above, the con-
clusion is identical, ie, that this combination of ABO blood 
group genotype and FV Leiden carrier state is a risk factor 
for the development of thrombosis. The Procare-GEHT (20) 
group investigated non-OO blood groups as risk factors for 
the development of thrombosis in homozygous FV Leiden 
carriers (OR, 4.1; 95% CI, 1.9-8.9). The prevalence of non-OO 
blood groups in patients with venous thromboembolism 
and control participants was assessed in the Longitudinal 
Investigation of Thromboembolism Etiology study (21). 
The authors reported on OR, 1.64 (95% CI, 1.32-2.05) in pa-
tients with venous thromboembolism and non-OO blood 
groups. The presence of FV Leiden additionally increased 
OR to 6.77. Interestingly, the Afro-Americans included in 
the study had a higher proportion of OO blood group and 
greater prevalence of venous thromboembolism, suggest-
ing that some risk factors other than blood group, eg, obe-
sity, diabetes mellitus, and elevated factor VIII level, also 
contribute to thrombotic risk (21).
In their meta-analysis, Wu et al (8) found OR of 3.88 for non-
OO and FV Leiden carriers, and none of the studies includ-
ed in the analysis had demonstrated an increasing effect 
of prothrombin 20210A mutation on the thrombotic risk. 
In our study, 20210A prothrombin gene mutation was not 
found to pose a significant risk factor in combination with 
OO and non-OO blood groups either. The OO carriers of 
prothrombin mutation did have a 6.7-fold predisposition 
to thrombosis development, but it was not significant. The 
non-OO carriers showed an even lower, non-significant 
potential to develop thrombosis (OR, 0.83). Similar results 
reported by Ordonez-Gonzalez et al (22) also suggest that 
this prothrombin gene mutation does not increase the risk 
of thrombosis.
Very informative are the results of study of Minano et al (23), 
which has analyzed the effect of genotypes of ABO blood 
groups on venous or arterial thrombosis in a great num-
ber of carriers (n=981) of FVL or prothrombin G20210A 
polymorphism. They reported that non-OO blood 
group did not increase the risk of myocardial infarction 
in carriers of FVL or prothrombin G20210A. Alternatively, 
their results confirmed the previously documented risk of 
VTE among FVL carriers who had a non-OO blood group 
(OR, 1.76). This is the first large study suggesting that non-
OO blood group increases the risk of VTE in carriers of pro-
thrombin polymorphism.
Our study has some limitations, such as the relatively small 
number of patients and controls, due to the non-existence 
or low frequency of prothrombotic carriers among partici-
pants. Additionally, the patient group is heterogenous with 
respect to presence of arterial thrombosis. However, tak-
ing into account only the subgroup of patients with ve-
nous thrombosis, the conclusions on association of non-
OO blood genotypes and prothrombotic polymorphisms 
is valid.
In this study, we also investigated the effect of methy-
lenetetrahydrofolate reductase C677T mutation in ho-
mozygous carriers, since heterozygous carrier state is not 
associated with an increased risk of thrombosis. When 
OO/methylenetetrahydrofolate reductase negative carri-
ers were compared with OO/methylenetetrahydrofolate 
reductase positive carriers, this combination of risk factors 
was not found to be significant.
Isolated methylenetetrahydrofolate reductase C677T mu-
tation is not a risk factor for thrombosis unless being as-
sociated with some other genetic or acquired risk factor, 
as demonstrated in our study as well as in other related 
studies (9,14,20).
The main conclusion of this study is that carriers of ABO 
blood group non-OO genotype have a slightly elevated 
twofold predisposition to develop thrombosis compared 
with that found in OO genotypes. FV Leiden mutation 
carriers are at an additional thrombotic risk, higher in OO 
blood group carriers.
ABO blood group genotyping in blood donors could pro-
duce valuable results for use in epidemiologic and anthro-
pologic studies in our population and which could serve as 
a basis for future research on the association between ABO 
system and various diseases.
In this study, the criteria for valid statistical analysis in terms 
of adequate and properly selected study population were 
met. Study results defined ABO system genotypes show-
ing significant correlation with the development of venous 
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and arterial thromboembolism, thus providing a valuable 
tool for the prevention and target management of these 
pathologies. We believe that these results will greatly con-
tribute to making proper decision whether ABO genotyp-
ing should be included in the mandatory risk testing in 
thromboembolism.
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